Fate Therapeutics Inc (NASDAQ: FATE)’s stock price has dropped by -8.46 in relation to previous closing price of 2.72. Nevertheless, the company has seen a loss of -17.82% in its stock price over the last five trading days. globenewswire.com reported 2024-10-02 that SAN DIEGO, Oct. 02, 2024 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on October 1, 2024 the Company granted restricted stock units (RSUs) representing 16,400 shares of its common stock to two newly-hired non-executive employees. The grants were approved by the Compensation Committee of the Company’s Board of Directors and granted under the Company’s Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employee being continuously employed by the Company through each vesting date.
Is It Worth Investing in Fate Therapeutics Inc (NASDAQ: FATE) Right Now?
The 36-month beta value for FATE is at 1.84. Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for FATE is 94.87M, and currently, shorts hold a 16.93% of that float. The average trading volume for FATE on October 31, 2024 was 1.34M shares.
FATE’s Market Performance
FATE stock saw a decrease of -17.82% in the past week, with a monthly decline of -25.67% and a quarterly a decrease of -48.98%. The volatility ratio for the week is 8.06%, and the volatility levels for the last 30 days are 6.48% for Fate Therapeutics Inc (FATE). The simple moving average for the last 20 days is -17.23% for FATE’s stock, with a simple moving average of -46.32% for the last 200 days.
Analysts’ Opinion of FATE
Many brokerage firms have already submitted their reports for FATE stocks, with Piper Sandler repeating the rating for FATE by listing it as a “Overweight.” The predicted price for FATE in the upcoming period, according to Piper Sandler is $6 based on the research report published on June 17, 2024 of the current year 2024.
Wells Fargo, on the other hand, stated in their research note that they expect to see FATE reach a price target of $6. The rating they have provided for FATE stocks is “Equal Weight” according to the report published on March 27th, 2023.
H.C. Wainwright gave a rating of “Neutral” to FATE, setting the target price at $7 in the report published on January 24th of the previous year.
FATE Trading at -26.80% from the 50-Day Moving Average
After a stumble in the market that brought FATE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -71.80% of loss for the given period.
Volatility was left at 6.48%, however, over the last 30 days, the volatility rate increased by 8.06%, as shares sank -22.43% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -32.15% lower at present.
During the last 5 trading sessions, FATE fell by -17.82%, which changed the moving average for the period of 200-days by -44.79% in comparison to the 20-day moving average, which settled at $3.01. In addition, Fate Therapeutics Inc saw -33.42% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at FATE starting from Xu Yuan, who sale 633 shares at the price of $4.23 back on Aug 06 ’24. After this action, Xu Yuan now owns 8,669 shares of Fate Therapeutics Inc, valued at $2,678 using the latest closing price.
Xu Yuan, the Director of Fate Therapeutics Inc, proposed sale 633 shares at $4.23 during a trade that took place back on Aug 06 ’24, which means that Xu Yuan is holding shares at $2,678 based on the most recent closing price.
Stock Fundamentals for FATE
Current profitability levels for the company are sitting at:
- -15.87 for the present operating margin
- -0.56 for the gross margin
The net margin for Fate Therapeutics Inc stands at -14.27. The total capital return value is set at -0.4. Equity return is now at value -42.10, with -31.56 for asset returns.
Based on Fate Therapeutics Inc (FATE), the company’s capital structure generated 0.2 points at debt to capital in total, while cash flow to debt ratio is standing at -1.4. The debt to equity ratio resting at 0.25. The interest coverage ratio of the stock is -20.13.
Currently, EBITDA for the company is -159.33 million with net debt to EBITDA at -0.35. When we switch over and look at the enterprise to sales, we see a ratio of 28.19. The receivables turnover for the company is 4.48for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.18.
Conclusion
In conclusion, Fate Therapeutics Inc (FATE) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
